Unconfigured Ad

Collapse
X
 
  • Time
  • Show
Clear All
new posts
  • alyse_c
    Junior Member
    • Jun 2022
    • 4

    #1

    PrecisionFDA's NCTR Indel Calling from Oncopanel Sequencing Data Challenge

    Reminder! We are less than one month out from the NCTR Indel Calling from Oncopanel Sequencing Data Challenge submission deadline! There’s still time to join the challenge.

    This challenge is being hosted in collaboration with the FDA’s National Center for Toxicological Research (NCTR) and is taking part in two phases.

    Phase 1 of the challenge will run through July 8th and Phase 2 will run from July 11th-July 26th.

    The primary goal of this challenge is to encourage the bioinformatics community to develop, validate, and benchmark indel calling pipelines to identify indels in oncopanel sequencing datasets. Given the widely recognized impact of indels on protein coding and function, it is crucial that the tools for indel-calling be rigorously evaluated and optimized.

    Winners of the challenge will be publicly recognized and invited to contribute to a manuscript and a webinar describing the challenge and their submission results. Visit the challenge site below to get started or to submit your results!

    https://go.usa.gov/xJw8B
    Last edited by alyse_c; 06-22-2022, 01:18 PM.
  • alyse_c
    Junior Member
    • Jun 2022
    • 4

    #2
    There are only a few days left to submit your results for the NCTR Indel Calling from Oncopanel Sequencing Data Challenge! Phase 1 closes on July 8th. Those who completed Phase 1 for both Oncopanel A & Oncopanel B will be able to participate in the optional Phase 2 that runs from July 11th-July 26th.

    Visit the site below to submit your final results!
    https://go.usa.gov/xJzdB


    Originally posted by alyse_c View Post
    Reminder! We are less than one month out from the NCTR Indel Calling from Oncopanel Sequencing Data Challenge submission deadline! There’s still time to join the challenge.

    This challenge is being hosted in collaboration with the FDA’s National Center for Toxicological Research (NCTR) and is taking part in two phases.

    Phase 1 of the challenge will run through July 8th and Phase 2 will run from July 11th-July 26th.

    The primary goal of this challenge is to encourage the bioinformatics community to develop, validate, and benchmark indel calling pipelines to identify indels in oncopanel sequencing datasets. Given the widely recognized impact of indels on protein coding and function, it is crucial that the tools for indel-calling be rigorously evaluated and optimized.

    Winners of the challenge will be publicly recognized and invited to contribute to a manuscript and a webinar describing the challenge and their submission results. Visit the challenge site below to get started or to submit your results!

    https://go.usa.gov/xJw8B

    Comment

    • alyse_c
      Junior Member
      • Jun 2022
      • 4

      #3
      Tomorrow is the last day to submit your results for the NCTR Indel Calling from Oncopanel Sequencing Data Challenge! Phase 1 closes on July 8th. The optional Phase 2 is open for only those who have completed Phase 1 and will run from July 11th-July 26th.

      Submit your results here: https://go.usa.gov/xSc6t


      Originally posted by alyse_c View Post
      There are only a few days left to submit your results for the NCTR Indel Calling from Oncopanel Sequencing Data Challenge! Phase 1 closes on July 8th. Those who completed Phase 1 for both Oncopanel A & Oncopanel B will be able to participate in the optional Phase 2 that runs from July 11th-July 26th.

      Visit the site below to submit your final results!
      https://go.usa.gov/xJzdB



      Comment

      Latest Articles

      Collapse

      • SEQadmin2
        Multiomic Liquid Biopsy: What DNA/RNA Panels Reveal That DNA Alone Can’t
        by SEQadmin2



        Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?

        Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating
        ...
        10-14-2026, 09:55 AM
      • SEQadmin2
        New Genomics Technologies Take Aim at Long-Standing Limits
        by SEQadmin2


        Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.

        We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing
        ...
        09-28-2026, 10:25 AM

      ad_right_rmr

      Collapse

      News

      Collapse

      Topics Statistics Last Post
      Started by SEQadmin2, Yesterday, 11:13 AM
      0 responses
      19 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, Yesterday, 10:48 AM
      0 responses
      18 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-15-2026, 10:52 AM
      0 responses
      36 views
      0 reactions
      Last Post SEQadmin2  
      Started by SEQadmin2, 10-14-2026, 05:39 AM
      0 responses
      42 views
      0 reactions
      Last Post SEQadmin2  
      Working...